SUNSHINE BIOPHARMA INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$9M
↓-10.6% -$1Mvs FY2024 (Q4)
Gross Profit
$3M
↓-2.1% -$64Kvs FY2024 (Q4)
Operating Income
$3M
↓-0.8% -$22Kvs FY2024 (Q4)
Net Income
$3M
↓-6.0% -$172Kvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $9M | $10M |
| COGS | $6M | $7M |
| Gross Profit | $3M | $3M |
| R&D | $74K | $149K |
| SG&A | $0 | $0 |
| D&A | $99K | $65K |
| Other OpEx | $0 | $0 |
| Operating Income | $3M | $3M |
| Interest Exp. | $0 | $9K |
| Other Non-Op | $0 | $0 |
| Pretax Income | $3M | $3M |
| Tax | $159K | $0 |
| Net Income | $3M | $3M |
QuarterCharts · SEC EDGAR data · SBFM · Comparing FY2025 (Q4) vs FY2024 (Q4)